<DOC>
	<DOCNO>NCT02425852</DOCNO>
	<brief_summary>PHASE : IV TYPE OF STUDY : With direct benefit . DESCRIPTIVE : Multicentre , randomize , open label study . INCLUSION CRITERIA : Acute severe ulcerative colitis . OBJECTIVES : To compare efficacy safety early administration combination therapy infliximab azathioprine steroid azathioprine patient acute severe ulcerative colitis treat intravenous steroid . STUDY TREATMENTS : All patient : Intravenous steroid ( 0.8 mg/kg/day methylprednisolone equivalent ) 5 day . Combination therapy arm : Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day . Azathioprine arm : Steroids taper 3 month Azathioprine 2-2.5 mg/kg/day .</brief_summary>
	<brief_title>A Randomized , Multicenter Open Label Study Comparing Early Administration Azathioprine Plus IFX Steroids Plus Azathioprine Acute Severe Colitis</brief_title>
	<detailed_description>NUMBER OF PATIENTS : 75 patient group i.e . total 150 patient . RECRUITMENT PERIOD : 24 month STUDY DURATION : 36 month PRIMARY END POINT : Treatment failure define : - Absence steroid-free remission W52 accord total Mayo Disease Activity Index score - OR Absence mucosal healing ( Mayo endoscopic subscore 0-1 ) - OR Adverse event lead treatment interruption - OR Colectomy - OR Death - OR Infliximab withdrawal combination therapy group OR Infliximab introduction azathioprine group SECONDARY END POINT : - Clinical response remission D7 , W14 W52 ( accord Lichtiger score total Mayo Disease Activity Index score ) - Endoscopic histological response - Mucosal healing ( partial endoscopic Mayo subscore 0 ) - Colectomy rate - Adverse event rate - Fecal calprotectin - Health-economic outcome</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age &gt; 18 year . Diagnosis UC accord LennardJones criterion ( Appendix 1 ) . Endoscopically demonstrated colorectal lesion localize anal margin extend least 15cm proximally ( Endoscopic Mayo subscore ≥ 2 ) . Acute flare require hospitalization Severe acute flare UC Lichtiger Index score &gt; 10 Day 3 Adequate contraception male female subject childbearing potential , continue throughout study least 3 month study termination . 3.2 EXCLUSION CRITERIA Pregnant breastfeed woman . Previous treatment infliximab , adalimumab OR golimumab . Azathioprine mercaptopurine treatment initiate 4 week inclusion . Ongoing intravenous steroid 48 hour time screen OR ongoing oral steroid &gt; 20 mg/day 4 week time screen Stool frequency &gt; 8 / day OR CRP &gt; 45 mg/L time inclusion Contraindication antiTNF therapy Indication immediate surgery . History colorectal dysplasia . Diagnosis Crohn 's disease indeterminate colitis Positive stool test amoebiasis and/or positive bacteriological culture Salmonella , Shigella , Yersinia Campylobacter and/or presence Clostridium difficile B toxin stool . Renal failure ( creatininemia &gt; upper limit normal laboratory value ) . Uncontrolled high blood pressure . HIV , HBV viral infection ( except presence positive antiHBs antibody ) serology old 3 month . Uncontrolled bacterial active viral infection . Past medical history malignant condition last 5 year ( include leukaemia , lymphoma myelodysplasia ) except basocellular cutaneous cancer . Past medical history myocardial infarction heart failure . Intradermal reaction Tuberculin ( Tubertest® 5 unit ) &gt; 5mm positive interferongamma release assay ( Quantiferon® ) Active tuberculosis Untreated latent tuberculosis ( see national recommendation . Appendix 2 ) . Abnormal blood count polynuclear neutrophil &lt; 1,500 G/L white cell &lt; 3,000 , platelet &lt; 100,000 G/L . Unexplained rise higher 3 time normal level transaminase , alkaline phosphatase and/or high twice normal level bilirubin . Severe acute chronic medical psychiatric condition may increase risk associate study participation investigational product administration may interfere interpretation study result , judgement investigator , would make subject inappropriate entry study . Subjects , opinion investigator , uncooperative unable comply study procedure . Participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>